SEC Company Response from Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299) — Mar 6, 2020
Kaleido Biosciences, Inc. (KLDO) (CIK 0001751299)
Date: March 6, 2020 · CIK: 0001751299 · Accession: 0001193125-20-065096
AI Filing Summary & Sentiment
File numbers found in text: 333-236804
Letter
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421
March 6, 2020
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Kaleido Biosciences, Inc.: Registration Statement on Form S-3 filed March 2, 2020 (File No. 333-236804)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kaleido Biosciences, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 10, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Laurie Burlingame of Goodwin Procter LLP at (617) 570-1879.
Sincerely,
Kaleido Biosciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Kaleido Biosciences, Inc. 65 Hayden Avenue Lexington, MA 02421 March 6, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kaleido Biosciences, Inc.: Registration Statement on Form S-3 filed March 2, 2020 (File No. 333-236804) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Kaleido Biosciences, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 10, 2020, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Laurie Burlingame of Goodwin Procter LLP at (617) 570-1879. Sincerely, Kaleido Biosciences, Inc. /s/ Alison Lawton Alison Lawton President and Chief Executive Officer cc: Jerald Korn, Kaleido Biosciences, Inc. Kingsley L. Taft, Esq., Goodwin Procter LLP Laurie Burlingame, Esq., Goodwin Procter LLP